CGON · CG Oncology, Inc.
$79.11
+0.88 (+1.12%)
At close · Aug 25
Market Cap
$7.07B
Shares
88.64M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.04M
+254.7%
FY2025
Net Income
-$161M
-82.9%
FY2025
Operating Margin
-4722.13%
+5345.1pp
FY2025
Diluted EPS
-$2.08
-47.5%
FY2025
Operating Cash Flow
-$132.35M
-68.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $6.23M | $4.04M | $1.14M | $204K | |
| $156.23M | $116.64M | $82.1M | $45.75M | |
| $91.08M | $73.53M | $33.7M | $9.9M | |
| — | $1.45M | $32K | $17K | |
| $157.84M | — | $115.81M | $55.65M | |
| -$252.62M | -$190.77M | -$114.67M | -$55.45M | |
| — | -4722.13% | -10067.25% | -27180.88% | |
| — | -$189.33M | -$114.63M | -$55.43M | |
| $28.48M | $29.93M | $26.62M | $6.9M | |
| $28.24M | $29.78M | $26.63M | $6.84M | |
| — | -$270K | $1000 | $1000 | |
| -$224.38M | -$161M | -$88.04M | -$48.61M | |
| — | -3985.02% | -7729.5% | -23826.96% | |
| — | -$161M | -$88.04M | -$67.8M | |
| USD/shares | — | -$2.08 | -$1.41 | -$15.65 |
| USD/shares | — | -$2.08 | -$1.41 | -$15.65 |
| shares | — | 77.3M | 62.5M | 4.33M |
| shares | — | 77.3M | 62.5M | 4.33M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 10.38×
EV/EBIT
—
Peer median 26.30×
P/E (TTM)
—
Peer median 20.25×
Peer medians compare against the 166 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Commercial and Development Revenue | $3,234,000 | $0 | $0 |
| License and Collaboration Revenue | $806,000 | $1,139,000 | $204,000 |
Key facts
CIK
1991792
CUSIP
156944100
13F (30d)
225 filings
218 filers
Visit website
Investor relations